These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 35732665)

  • 1. RNase III-CLASH of multi-drug resistant Staphylococcus aureus reveals a regulatory mRNA 3'UTR required for intermediate vancomycin resistance.
    Mediati DG; Wong JL; Gao W; McKellar S; Pang CNI; Wu S; Wu W; Sy B; Monk IR; Biazik JM; Wilkins MR; Howden BP; Stinear TP; Granneman S; Tree JJ
    Nat Commun; 2022 Jun; 13(1):3558. PubMed ID: 35732665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The functional small RNA interactome reveals targets for the vancomycin-responsive sRNA RsaOI in vancomycin-tolerant
    Wu W; Pang CNI; Mediati DG; Tree JJ
    mSystems; 2024 Apr; 9(4):e0097123. PubMed ID: 38534138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The 3' UTR of vigR is required for virulence in Staphylococcus aureus and has expanded through STAR sequence repeat insertions.
    Mediati DG; Dan W; Lalaouna D; Dinh H; Pokhrel A; Rowell KN; Michie KA; Stinear TP; Cain AK; Tree JJ
    Cell Rep; 2024 Apr; 43(4):114082. PubMed ID: 38583155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic pathway in acquisition and loss of vancomycin resistance in a methicillin resistant Staphylococcus aureus (MRSA) strain of clonal type USA300.
    Gardete S; Kim C; Hartmann BM; Mwangi M; Roux CM; Dunman PM; Chambers HF; Tomasz A
    PLoS Pathog; 2012 Feb; 8(2):e1002505. PubMed ID: 22319446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA among methicillin-resistant S. aureus with high vancomycin minimal inhibitory concentrations in Taiwan: A multicenter surveillance study, 2012-2013.
    Huang SH; Chen YC; Chuang YC; Chiu SK; Fung CP; Lu PL; Wang LS; Wu TL; Wang JT
    J Microbiol Immunol Infect; 2016 Oct; 49(5):701-707. PubMed ID: 26320398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cervimycin-Resistant Staphylococcus aureus Strains Display Vancomycin-Intermediate Resistant Phenotypes.
    Dietrich A; Steffens U; Gajdiss M; Boschert AL; Dröge JK; Szekat C; Sass P; Malik IT; Bornikoel J; Reinke L; Maček B; Franz-Wachtel M; Nieselt K; Harbig T; Scherlach K; Brötz-Oesterhelt H; Hertweck C; Sahl HG; Bierbaum G
    Microbiol Spectr; 2022 Oct; 10(5):e0256722. PubMed ID: 36173303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clonal dissemination of meticillin-resistant and vancomycin-intermediate Staphylococcus aureus in a Taiwanese hospital.
    Hsueh PR; Lee SY; Perng CL; Chang TY; Lu JJ
    Int J Antimicrob Agents; 2010 Oct; 36(4):307-12. PubMed ID: 20685086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of Slow-Growth Vancomycin Nonsusceptibility in Methicillin-Resistant Staphylococcus aureus.
    Katayama Y; Azechi T; Miyazaki M; Takata T; Sekine M; Matsui H; Hanaki H; Yahara K; Sasano H; Asakura K; Takaku T; Ochiai T; Komatsu N; Chambers HF
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28827421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RNase III CLASH in MRSA uncovers sRNA regulatory networks coupling metabolism to toxin expression.
    McKellar SW; Ivanova I; Arede P; Zapf RL; Mercier N; Chu LC; Mediati DG; Pickering AC; Briaud P; Foster RG; Kudla G; Fitzgerald JR; Caldelari I; Carroll RK; Tree JJ; Granneman S
    Nat Commun; 2022 Jun; 13(1):3560. PubMed ID: 35732654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Publisher Correction: RNase III-CLASH of multi-drug resistant Staphylococcus aureus reveals a regulatory mRNA 3'UTR required for intermediate vancomycin resistance.
    Mediati DG; Wong JL; Gao W; McKellar S; Pang CNI; Wu S; Wu W; Sy B; Monk IR; Biazik JM; Wilkins MR; Howden BP; Stinear TP; Granneman S; Tree JJ
    Nat Commun; 2022 Sep; 13(1):5683. PubMed ID: 36167839
    [No Abstract]   [Full Text] [Related]  

  • 11. Contribution of selected gene mutations to resistance in clinical isolates of vancomycin-intermediate Staphylococcus aureus.
    Hafer C; Lin Y; Kornblum J; Lowy FD; Uhlemann AC
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5845-51. PubMed ID: 22948864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the Presence and Characterization of Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Level Resistance Among Bloodstream Isolates of Methicillin-Resistant
    Ozmen Capin BB; Tekeli A; Karahan ZC
    Microb Drug Resist; 2020 Mar; 26(3):238-244. PubMed ID: 31545160
    [No Abstract]   [Full Text] [Related]  

  • 13. Profiling the in vivo RNA interactome associated with the endoribonuclease RNase III in Staphylococcus aureus.
    Wu W; Pang CNI; Tree JJ; Mediati DG
    Methods Enzymol; 2023; 692():299-324. PubMed ID: 37925184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emergence of vancomycin-intermediate and -resistant Staphylococcus aureus among methicillin-resistant S. aureus isolated from clinical specimens in the northwest of Iran.
    Ghahremani M; Jazani NH; Sharifi Y
    J Glob Antimicrob Resist; 2018 Sep; 14():4-9. PubMed ID: 29454049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Role of β-Glycosylated Wall Teichoic Acids in the Reduction of Vancomycin Susceptibility in Vancomycin-Intermediate Staphylococcus aureus.
    Hort M; Bertsche U; Nozinovic S; Dietrich A; Schrötter AS; Mildenberger L; Axtmann K; Berscheid A; Bierbaum G
    Microbiol Spectr; 2021 Oct; 9(2):e0052821. PubMed ID: 34668723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia.
    Howden BP; Johnson PD; Ward PB; Stinear TP; Davies JK
    Antimicrob Agents Chemother; 2006 Sep; 50(9):3039-47. PubMed ID: 16940100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of the small RNA transcriptional response in multidrug-resistant Staphylococcus aureus after antimicrobial exposure.
    Howden BP; Beaume M; Harrison PF; Hernandez D; Schrenzel J; Seemann T; Francois P; Stinear TP
    Antimicrob Agents Chemother; 2013 Aug; 57(8):3864-74. PubMed ID: 23733475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complete Reconstitution of the Vancomycin-Intermediate Staphylococcus aureus Phenotype of Strain Mu50 in Vancomycin-Susceptible S. aureus.
    Katayama Y; Sekine M; Hishinuma T; Aiba Y; Hiramatsu K
    Antimicrob Agents Chemother; 2016 Jun; 60(6):3730-42. PubMed ID: 27067329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A vancomycin resistance-associated WalK(S221P) mutation attenuates the virulence of vancomycin-intermediate Staphylococcus aureus.
    Rao Y; Peng H; Shang W; Hu Z; Yang Y; Tan L; Li M; Zhou R; Rao X
    J Adv Res; 2022 Sep; 40():167-178. PubMed ID: 36100324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel mutation of walK confers vancomycin-intermediate resistance in methicillin-susceptible Staphylococcus aureus.
    Zhu J; Liu B; Shu X; Sun B
    Int J Med Microbiol; 2021 Feb; 311(2):151473. PubMed ID: 33445057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.